Darusentan

This classification denotes an endothelin receptor antagonist and antihypertensive agent with the molecular formula C22H22N2O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 33JD57L6RW, chemically known as benzenepropanoic acid, alpha-((4,6-dimethoxy-2-pyrimidinyl)oxy)-beta-methoxy-beta-phenyl-, (s)- but generally known as darusentan, which bears US NIH Compound Identifier 177236. European Medicines Agency schedules Darusentan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB32910. The term DARUSENTAN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 14, No. 3, 2000, List 44). Most nations schedule darusentan under HS 29335995 and SITC 51576. As of Q4 2014, DARUSENTAN remains the US FDA Preferred Term for this commodity. Darusentan bears US NLM identifiers UMLS ID C0665087 and NCI Concept Code C75991. SMILES: O(C(C(Oc1nc(OC)cc(OC)n1)C(=O)O)(c1ccccc1)c1ccccc1)C.